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Abstract 
The genetic risk of differentiated thyroid cancer (DTC) probably consists of multiple low-penetrance, single-nucleotide polymorphisms 
(SNP). Such markers are difficult to uncover by linkage analysis but can be revealed by association studies. Genome-wide association 
studies (GWASs) have uncovered 31 SNPs associated with DTC. These markers carry a low to moderate risk for DTC, but their cumula-
tive effect increases with each successive risk allele. These data support the important contribution of low penetrance variants in the 
pathogenesis of DTC. Contrary to somatic mutations such as BRAFV600E, germline variants can be ascertained prior to surgical treatment. 
Therefore, we hypothesise that GWAS SNPs might impact the clinical course of DTC and we can benefit from this knowledge in choosing 
a treatment strategy. Several associations between clinical factors and GWAS markers have been reported so far. The most important are 
associations between rs966423 and mortality (HR = 1.60, p = 0.038), extrathyroidal extension (ETE) (OR = 1.57, p = 0.019); rs965513 and 
tumour diameter (slope of regression 0.14, p = 0.025), lymph node metastasis (OR = 1.59, p = 0.030) and ETE (OR = 1.29, p = 0.045); 
rs944289 and distant metastasis (OR = 0.58, p = 0.042); and rs116909374 and lymph node metastasis (OR = 0.61, p = 0.016). These findings 
show that GWAS SNPs are not only the ignition factors (together with environmental factors) for malignant transformation of thyrocytes 
but might also impact the clinical course of DTC. Surprisingly, it is not always the risk allele for DTC that is associated with worse clini-
cal outcome. The second interesting observation is that GWAS SNPs show different associations with DTC clinical features depending 
on their histological subtypes. These point to the complexity of DTC with putatively different roles of genes at different stages of DTC 
development. (Endokrynol Pol 2019; 70 (5): 423–429)
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Introduction 
Thyroid carcinoma (TC) displays one of the strongest 
familiarities among cancers. Large case-control studies 
analysing populations from Utah and Sweden showed 
that the family risk ratio (FRR) for first-degree relatives 
of probands was 8.48 and 12.42, respectively [1–3]. 
Such data suggest a strong genetic component in TC 
development. However, it remained unclear whether 
the reported familiarity in TC was due to the domi-
nant role of genes or the influence of common familial 
environmental factors. One study addressed this issue 
and estimated that half of TC familiarity was related to 
genetic factors, the highest of all analysed tumors. After 
TC, the cancers with the highest genetic component 
were other endocrine tumours (28%), testicular car-
cinoma (25%), and breast carcinoma (25%) [4]. These 
findings show the important role of genetic alterations 
in TC development. 
One of the most potent risk factors for both sporadic 
and hereditary medullary thyroid carcinoma (MTC) 
is a mutation in the RET proto-oncogene. Hereditary 
MTC, which is a part of multiple endocrine neoplasia 
2 (MEN2) syndromes and familial MTC (FMTC), is as-
sociated with RET germline mutations. Furthermore, 
approximately up to 50% of sporadic MTC possess 
somatic mutations in RET [5–7]. While genetic factors 
have a clear basis in MTC development, this type of 
carcinoma accounts for only 5% of all TC cases. The 
majority of TC comprises papillary thyroid carcinoma 
(PTC) and follicular thyroid carcinoma (FTC), which 
together are termed as differentiated thyroid carcinoma 
(DTC) [8]. Data from studies focusing on DTC showed 
that the Standard Incidence Risk (SIR) of DTC was 
between 7.8 and 4.1 for male relatives and between 4.9 
and 1.9 for female relatives of the proband [9–11]. For 
PTC, which is the most common histological subtype 
of TC, the SIR was calculated as 5.8 and 4.1 for male 
and female relatives, respectively [11]. Although the 
SIR for DTC was lower overall than for TC, it remains 
relatively high in comparison to other cancers. For 
instance, in breast cancer, where well-known BRCA1 
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the first SNP microarray containing 500 variants [14]. 
Five years later a commercial microarray, GeneChip 
Mapping 10K by Affymetrix, already contained 10,000 
SNPs; in 2007 microarrays by Affymetrix and Illumina 
containing 1 million SNPs were available [15]. Together 
these achievements allowed for the investigation of the 
entire human genome by association study, ushering in 
the era of the genome-wide association study (GWAS). 
The first GWAS, published in 2005, was a milestone 
in modern genetics. Genomic DNA from 96 patients 
with age-related macular degeneration (AMD) versus 
50 healthy controls was genotyped on the Affymetrix 
GeneChip Mapping 100K platform. This uncovered 
the association of a novel variant, rs380390, located in 
the intron of the complement factor H (CFH) gene, with 
AMD. The odds ratio (OR) carried by rs380390 was 7.4 
(p < 10–7), and it has remained one of the highest for 
GWAS SNPs [16]. Interestingly, CFH had not been iden-
tified as being involved in AMD pathogenesis prior to 
the rs380390 report. Further research delivered data elu-
cidating the role of CFH in AMD pathogenesis [17–19]. 
The results of the first GWAS indicated the potential of 
GWAS in revealing mechanisms of complex diseases. 
More than 3600 GWAS studies have been published 
to date, including eight for DTC. (https://www.ebi.
ac.uk/gwas, accessed January 2019). For DTC, 31 as-
sociations have been reported (Tab. I) [20–27]. SNPs 
uncovered by GWAS are located on 12 chromosomes 
in 17 different loci. Loci with the most “dense” SNPs 
are 9q22 and 14q13, containing five and four variants, 
respectively. Interestingly, 9q22 and 14q13 harbour thy-
roid transcription factors (9q22: FOXE1; 14q13: NKX2-1) 
that are involved in thyroid development [21, 28]. The 
remaining variants are in the vicinity of genes that 
have not been directly implicated in thyroid function. 
DTC-associated GWAS SNPs carry a risk varying from 
1.20 to 2.09, with the majority being below 1.50. Such 
moderate ORs are consistent with the observations from 
other cancers, in which the effect of polymorphisms 
was usually small (OR < 2.0) [29]. 
GWAS mainly uses platforms containing frequent 
genetic variants. Therefore, according to the common 
disease-common variant  (CD-CV) theory, the biological 
effect carried by these polymorphisms should be small 
[30]. However, regarding the relatively strong genetic 
component in DTC, their risk seems to be surprisingly 
moderate. This could be explained in part by a poly-
genic background, with many low-penetrance genes 
contributing to DTC development. For example, a DTC 
polygenic risk model showed that each risk allele of 
the first five reported GWAS SNPs (rs965513, rs944289, 
rs966423, rs2439302, and rs116909374) increased the OR 
for PTC by 1.51 and 1.35 in the United States (US) and 
Polish populations, respectively [31]. Individuals with 
and BRCA2 mutations are prevalent, family risk ratio 
was assessed at 1.83–2.01 [3]. 
DTC shows familial occurrence, which means that at 
least two first-degree relatives of a proband are affected 
by DTC. Familial DTC accounts for approximately 10% 
of all DTC cases. If the genetic background of DTC is 
strong, linkage analyses should easily uncover predis-
posing loci in affected families. However, such linkage 
analyses have identified only a handful of genes; driver 
mutations existed in single families and they were ab-
sent in sporadic DTC [12]. Therefore, it seems that the 
genetic predisposition to DTC is probably polygenic 
with low-penetrance genes involved. Such genetic 
alterations are difficult to uncover by linkage but may 
be revealed by association studies.
Genome-wide association studies in DTC
Linkage analysis is the first-choice approach in search-
ing for predisposing genes with traits of a Mendelian 
pattern of inheritance. However, if low-penetrance 
genes are involved, this approach may not identify 
candidate loci and therefore other methods could be 
employed, such as association studies. Association 
studies are based on analysis of the allelic distribution 
between two populations: individuals with a given 
trait and a control group. By this approach we are able 
to detect genetic alterations that are more frequent in 
a tested population and hence are associated with a dis-
ease. Association studies are based mainly on analysis of 
single nucleotide polymorphisms (SNP), but also copy 
number variants (CNV), repetitive elements, or other 
more complex genetic alterations. In order to analyse 
the whole human genome, association studies require 
genotyping of hundreds of thousands of SNPs. There-
fore, association studies are focused on selected frag-
ments of human DNA where putative culprit genes 
might be located. The selection of such DNA regions is 
based on the function of genes associated with cancer 
development pathways, such as cell differentiation and 
growth, or DNA repair. This strategy, called a “gene 
candidate approach”, relies on a priori knowledge 
about the location and function of genes involved in 
the aforementioned pathways. However, in order to 
uncover novel genes that are important for cancer de-
velopment, an agnostic screening across the genome 
must be performed. With the HapMap Project it was 
estimated that around 500,000 SNPs were required in 
order to capture most of the genetic variation in the hu-
man genome [13]. However, at that time commercially 
available SNP arrays were largely prohibitive due to 
their low coverage and high costs. In 1998 a research 
group from Whitehead Institute from the Massachu-
setts Institute of Technology published a project using 
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seven or more risk alleles had ORs calculated at 13.38 
and 6.16, respectively. Data from the US and Polish 
populations were concomitant, although cumulative 
ORs for the latter were clearly lower. This difference is 
probably due to population heterogeneity, unknown 
environmental factors, and/or the fact that Polish con-
trols were younger than cases [27, 31].
The additive effect of GWAS markers was also 
shown in Italian and Han populations. The cumulative 
effect of 11 independent susceptibility SNPs in an Italian 
population (n = 1791 DTC cases and n = 1588 controls) 
showed an increase of DTC risk by OR = 1.30 per al-
lele. Individuals with 14 or more risk alleles had a 7.68 
times higher risk compared to those with seven or less 
risk alleles. When rs9655113 was added to the model, 
the risk of DTC increased to 27.45 [32]. The analysis of 
the cumulative effect of four GWAS SNPs (rs965513, 
rs944289, rs966423, and rs2439302) in Chinese PTC 
cases (n = 838) showed that individuals with more 
than five risk alleles had an 8.84-fold increased risk 
of PTC compared to those with one risk allele [33]. 
Of note, in Ohio, Polish, and Italian populations the 
Table I. Single-nucleotide polymorphisms (SNP) reported by genome-wide association studies (GWAS) conducted 
in non-medullary thyroid carcinoma (NMTC)
Region SNP [risk allele] Reported gene(s) Risk allele frequency OR 95% CI p value Reference
1q42.2 rs12129938[A] PCNXL2 0.80 1.32 1.20–1.43 4.00E-11 [20]
1q42.2 rs4649295[T] PCNXL2 0.82 1.43 NR 6.00E-08 [25]
1p13.3 rs4915076[T] VAV3 0.70 1.33 NR 8.47E-08 [25]
2q35 rs966423[C] DIRC3 0.44 1.34 1.22–1.47 1.30E-09 [22]
2q35 rs6759952[T] DIRC3 0.43 1.25 1.16–1.34 6.40E-10 [26]
2q35 rs11693806[C] DIRC3 0.32 1.43 1.33–1.54 1.50E-24 [20]
2q35 rs12990503[G] DIRC3 0.63 1.34 NR 3.55E-09 [25]
3q26.2 rs6793295[T] LRRC34, TERC 0.76 1.23 1.15–1.33 2.70E-08 [20]
3p14.2 rs9858271[G] FHIT 0.43 1.26 NR 6.82E-07 [25]
4q21.1 rs1874564[G] SEPT11 0.69 1.31 NR 2.04E-07 [25]
5p15.33 rs10069690[T] TERT 0.28 1.20 1.12–1.29 3.20E-07 [20]
5q22.1 rs73227498[A] NREP, EPB41L4A 0.87 1.37 1.23–1.49 3.00E-10 [20]
8p12 rs2439302[G] NRG1 0.35 1.36 1.23–1.50 2.00E-09 [22]
8p12 rs2466076[G] NRG1 0.48 1.32 1.23–1.41 1.50E-17 [20]
8p12 rs6996585[G] NRG1 0.23 1.39 NR 1.08E-10 [25]
9q22.33 rs965513[A] FOXE1, PTCSC2 0.34 1.75 1.59–1.94 1.70E-27 [21]
9q22.33 rs965513[A] FOXE1 0.33 1.65 1.43–1.91 4.80E-12 [23]
9q22.33 rs10122541[G] FOXE1 0.33 1.54 1.40–1.70 1.10E-17 [24]
9q22.33 rs7037324[A] FOXE1, C9orf156 0.34 1.54 1.39–1.70 1.20E-17 [24]
9q22.33 rs1588635[A] KRT18P13, FOXE1 0.40 1.69 1.59–1.82 2.00E-58 [20]
9q22.33 rs72753537[C] FOXE1 0.07 1.41 NR 7.67E-06 [25]
10q24.33 rs7902587[T] OBFC1 0.11 1.41 1.27–1.56 5.40E-11 [20]
12q14.3 rs11175834[T] MSRB3 0.15 1.37 NR 4.26E-08 [25]
14q13.3 rs944289[T] NKX2-1, PTCSC3 0.57 1.37 1.24–1.52 2.00E-09 [21]
14q13.3 rs116909374[T] MBIP, RN7SKP21 0.02 2.09 1.68–2.60 4.60E-11 [22]
14q13.2 rs368187[G] LOC105370452 0.58 1.39 1.30–1.47 5.10E-23 [20]
14q13.2 rs34081947[T] NKX2-1 0.41 1.27 NR 1.19E-07 [25]
14q24.3 rs10136427[C] BATF 0.87 1.40 1.23–1.60 4.35E-07 [27]
15q22.33 rs2289261[C] SMAD3 0.68 1.23 1.15–1.32 3.10E-09 [20]
15q22.33 rs56062135[T] SMAD3 0.25 1.24 1.16–1.34 4.90E-09 [20]
20q12 rs7267944[C] DHX35 0.23 1.39 1.24–1.56 2.13E-08 [27]
OR — odds ratio; CI — confidence interval; NR — non releasable
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analysed variants explained only 11%, 6%, and 4% of 
DTC risk, respectively [31–33]. These data clearly show 
that there are many undiscovered variants associated 
with DTC. Furthermore, the cumulative effect of GWAS 
SNPs suggests that by uncovering novel variants these 
cumulative risk scores will achieve clinical utility. For 
example, if we could identify potentially more aggres-
sive forms of DTC using GWAS SNPs genotyped from 
germline DNA, it would be of great clinical significance 
in treatment strategies for patients with high risk of 
a poorer outcome.
Association of GWAS markers with clinical 
features
There are several staging systems created to predict 
clinical outcome in DTC patients. Among them, 
the Union for International Cancer Control/TNM 
(UICC/TNM) is the most commonly used because of 
its relatively stable and replicable prediction of clinical 
outcome in various populations worldwide [34]. The 
UICC/TNM describes tumour size (T), and lymph node 
(N) and distant metastasis (M) presence [35]. Although 
the UICC/TNM classification is widely accepted, it has 
some disadvantages. First, it explains (as other DTC 
staging systems) only a small proportion of thyroid 
carcinoma-related deaths. Second, this system fails 
to predict persistence/recurrence of the disease [36]. 
Thyroid carcinoma is a complex disease with many 
factors impacting the final outcome such as different 
histological subtypes, localisation of metastases, mo-
lecular profiling, effectiveness of the initial treatment, 
which are not considered by the TNM system. Despite 
its limitations, TNM remains the main staging system 
for DTC. Therefore, studies for clinical associations 
between GWAS markers and clinical variables have 
focused primarily on associations with tumour, lymph 
node, and distant metastases.
T stage
Tumour diameter measured at the time of diagnosis is 
the result of many factors, including cancer growth rate, 
but also others that are not related to cancer biology, such 
as patient compliance and guidelines for performing 
a fine-needle aspiration biopsy. Although many factors 
are involved in tumor growth, one of them is cancer 
aggressiveness. Two GWAS variants (rs965513 and 
rs966423) showed association with tumor size at the time 
of diagnosis (slope of regression 0.14, and OR = 1.24, 
respectively). These associations were detected in both 
PTC and DTC populations (Tab. II). Variant rs965513 is 
located at 9q22.33 in close proximity to Forkhead Box E1 
(FOXE1) (also known as Thyroid Transcription factor 2). 
Follow-up studies showed that rs965513 overlapped 
with a bidirectional promoter shared by FOXE1 and 
a large non-coding RNA (lncRNA) gene called Papillary 
Thyroid Carcinoma Susceptibility Candidate 2 (PTCSC2). 
The latter was downregulated in PTC tumor tissue, 
and its suppression was stronger in the presence of 
the 965513 risk allele [37, 38]. PTCSC2 acted as a tu-
mor suppressor by reverting the promoter inhibition 
caused by myosin-9 (MYH9) [39]. These findings were 
fundamental in elucidating the role of rs965513 in PTC 
predisposition. Rs965513 is one of the most prominent 
DTC variants replicated in many populations [40]. 
Interestingly, it has shown an association with tumour 
diameter in classical PTC (cPTC, n = 891) but not in fol-
licular variant PTC (fvPTC, n = 243) (Tab. II). This may be 
related to its stronger association with cPTC compared 
to fvPTC [41]. Such association differences might sug-
gest that PTC is not homogeneous in terms of genetic 
background, and different genes might be involved in 
different histological subtypes [42].
N stage
Spread to local lymph nodes is not a high-risk factor 
for a poor outcome unless there are multiple large me-
tastases [43–45]. However, the presence of lymph node 
metastasis always requires radioactive iodine therapy in 
microPTC [34]. Three SNPs displayed association with 
N stage (rs965513, rs116909374, and rs2439302). The risk 
allele of rs116909374 was associated with nearly 50% 
lower relative risk of lymph node metastasis in a large 
Ohio cohort of 1216 PTC cases. Of note, this associa-
tion was probably entirely coming from fvPTC cases 
where rs116909374 was strongly associated with N1, 
whereas it did not show association with N stage for 
cPTC patients. Rs116909374, together with neighbour-
ing rs944289, carried a higher risk for fvPTC compared 
to cPTC [41]. These data are consistent with a report 
showing a smaller rate of lymph node metastasis in 
fvPTC [46]. In a very recent GWAS study analysing 
the genetic background of thyroid nodules one vari-
ant was associated with the trait 9q12: rs4745021, and 
a second (14q13.3: rs944289) showed a trend towards 
genome-wide significance [47]. The other GWAS SNPs 
analysed in the study did not show association with 
thyroid nodules [47]. SNP rs944289 was associated with 
benign thyroid tumors in two other populations [48, 49]. 
This suggests that the genetic backgrounds of benign 
and malignant thyroid tumors only partially overlap.
M stage
Distant metastasis is the hallmark of cancer progres-
sion and is one of the most important risk factors for 
DTC-related mortality. So far, there has been only one 
GWAS variant (rs944289) reported to be associated with 
M stage. The risk allele of rs944289 was associated with 
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approximately 50% reduction in the frequency of distant 
metastases in cPTC (Tab. II). This seems conflicting, but 
the same SNP might act differently according to differ-
ent stages of tumor development [50, 51]. The risk alleles 
of rs944289 and rs116909374 showed protective action 
against distant and lymph nodes metastases, respectively. 
While the mechanism by which rs116909374 predis-
poses to DTC remains unknown, more is known about 
rs944289 and its impact on PTC pathogenesis. This SNP 
is located 3.2 kb upstream from a lncRNA called Papillary 
Thyroid Carcinoma Susceptibility Candidate 3 (PTCSC3). 
The risk allele weakens the promoter activity caused by 
the CCAAT/enhancer binding proteins (C/EBP). PTCSC3 
was suppressed in PTC tissue, and its suppression was 
stronger in the presence of rs944289 risk allele [49, 52]. 
Additionally, rs944289 is located approximately 337 kb 
from the NK2 Homeobox 1 (NKX2-1) gene, also known 
as Thyroid Transcription Factor 1 (TTF1). Although this 
transcript remains a putative target for the 14q13.3 vari-
ants, no such biological link has been proven thus far 
[21]. Interestingly, the first-reported GWAS loci, 9q22.22 
and 14q13.3, contain two lncRNA genes that have been 
shown to be involved in the development of PTC [37, 
52]. Therefore, it seems that dysregulation of lncRNAs 
might be of great importance in PTC pathogenesis [53]. 
Extrathyroidal extension and multifocality
Two variants (rs965513 and rs966423) have shown 
an association with ETE (Tab. II). These variants seem 
to be the most interesting in terms of clinical associa-
tions. Rs965513 was also associated with tumor diam-
eter, N1 stage, and lack of lymphocytic infiltration [41, 
54]. The latter has been associated with a favourable 
prognosis with a diminished recurrence rate [55]. 
Rs966423 showed association with the overall mortality, 
which is discussed in greater detail below [50]. 
SNPs rs944289 and rs24390302 were associated with 
multifocality [33, 41]. Multifocality may increase the risk 
of lymph node metastases, which in turn is important 
for determining treatment [56]. Rs944289 has been 
linked with multifocality in Asian PTC patients (n = 838) 
[33]. In PTC cases from central Ohio (n = 1216) no as-
sociation with multifocality for rs944289 was detected 
[41]; this might reflect a different impact of GWAS on 
the clinical course depending on the population, but 
such findings need to be further validated.
Table II. Associations between genome-wide association studies (GWAS) single-nucleotide polymorphisms (SNPs) and clinical 
features 
SNP Feature Risk p value Reference
DTC
rs965513 N stage OR = 1.59 (1.11–2.29) 0.030 [54]
rs944289 Multifocality OR = 0.68 (0.53–0.88) 0.003 [33]
rs966423
T stage OR = 1.24 (1.02–2.51) 0.031 [33]
ETE OR = 1.57 (1.08–2.30) 0.019 [33]
Mortality HR = 1.60 (1.02–2.49) 0.038 [50]
PTC
rs965513
Tumour diameter Slope of regression 0.14 (0.02–0.27) 0.025 [41]
ETE OR = 1.29 (1.01–1.67) 0.045 [41]
rs116909374 N1 stage OR = 0.61 (0.41–0.90) 0.016 [41]
rs2439302
N1 stage OR = 1.24 (1.04–1.49) 0.016 [41]
Multifocality OR = 1.24 (1.05–1.48) 0.012 [41]
cPTC
rs965513 Tumour diameter Slope of regression 0.20 (0.06–0.34) 0.006 [41]
rs944289 M1 stage OR = 0.58 (0.34–0.98) 0.042 [41]
fvPTC
rs116909374 N1 stage OR = 0.29 (0.07–0.87) 0.049 [41]
rs966423 Age at time of diagnosis Slope of regression 2.39 (0.02–4.77) 0.048 [41]
rs2439302 Age at time of diagnosis Slope of regression 3.36 (0.93–5.80) 0.007 [41]
microPTC
rs2439302 ETE OR = 2.55 (1.13–6.33) 0.032 [41]
DTC — differentiated thyroid carcinoma; PTC — papillary thyroid carcinoma; ETE — extrathyroidal extension; OR — odds ratio; HR — hazard ratio
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Overall cancer-related mortality is the ultimate measure 
of clinical outcome in malignant diseases. In a large 
study of DTC cases (n = 1826), five GWAS variants were 
analysed (rs116909374, rs965513, rs944289, rs966423, and 
rs2439302) for their association with clinical features, 
including overall mortality [50]. The median follow-up 
in the study was 8.7 years with the overall mortality of 
85 cases (4.63%), including 53 deaths for cPTC (3.71%), 
15 for fvPTC (6.17%), 10 for FTC (35%), and seven for 
insular FTC (35%). Only one variant displayed as-
sociation with poor clinical outcome. Genotype “TT” 
vs. genotypes “CT” and “CC” of rs966423 was associated 
with overall increased mortality (Tab. II). The mortality 
rate was twice as high in patients with the risk geno-
type (6.4% vs. 3.7%). Rs966423 showed association with 
mortality regardless of the other risk factors such as 
ETE, distant metastases, and angiovascular invasion. 
Rs966423 is located at 2q35 locus within a lncRNA called 
Disrupted In Renal Carcinoma 3 (DIRC3). DIRC3 was origi-
nally identified in 2003 as a fusion transcript involved 
in familial renal carcinoma [57]; however, there have 
been no data showing involvement of DIRC3 in DTC 
pathogenesis. Similar to the association of rs944289 with 
distant metastases, it was not the risk allele of rs966423 
that displayed association with mortality. These find-
ings underscore the complexity of DTC genetics with 
variants acting differentially depending on stage of 
DTC development, but also suggests the presence of 
additional undiscovered disease-associated variants.
Conclusions
Genetic predisposition to DTC seems to be relatively 
strong based on population case-control studies. So 
far, eight GWASs conducted in DTC have yielded more 
than 31 genetic DTC-associated variants. It has been 
shown that the cumulative genetic risk score increases 
by adding variants. Hence, it is likely that multiple low 
penetrance genes are involved in DTC. Hopefully, the 
discovery of more DTC-associated SNPs will improve 
cumulative risk modelling, resulting in significant utility 
for clinicians and patients alike.
Only a few studies have analysed association be-
tween GWAS markers and clinical features. Such studies 
are difficult due to differences in clinical guidelines, 
heterogeneity of populations, the proportions of DTC 
histological subtypes, and more. Despite a low risk of 
variants for DTC predisposition, several interesting 
clinical associations have been detected in different 
populations worldwide. Markers associated with DTC 
have shown association with tumor diameter (rs965513, 
rs966423), N stage (rs965513, rs116909374, rs2439302), 
M stage (rs944289), ETE (rs965513, rs966423), and mul-
tifocality (rs944289, rs2439302). One variant (rs966423) 
showed association with increased mortality in DTC 
cases, whereas the DTC risk allele for rs966423 was 
associated with favourable outcome. Overall, these 
studies demonstrate that genetic markers not only carry 
a risk for DTC, but they also might influence the clinical 
course of the disease.
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